文献速递中医骨伤中药与中成药合理使用

藤黄健骨片治疗膝骨关节炎:中国前瞻性多中心注册研究

Tenghuang Jiangu tablet in knee osteoarthritis therapy: A prospective multicenter registry study in China.
PubMed 文献 · J Ethnopharmacol · 2025-02-27

该前瞻性多中心注册研究纳入50-75岁膝骨关节炎患者2995例,按治疗方式分为藤黄健骨片组、常规治疗组及联合组,疗程8周。结果显示三组VAS与WOMAC评分均显著改善,藤黄健骨片组VAS优于常规治疗组,不良事件少于常规治疗及联合组。

要点

  • 藤黄健骨片可显著改善膝骨关节炎患者VAS与WOMAC评分。
  • 藤黄健骨片组不良事件少于常规治疗组和联合治疗组。
  • 倾向评分匹配后藤黄健骨片组WOMAC疼痛与僵硬评分低于NSAID组。

核心结论

  • 藤黄健骨片治疗膝骨关节炎有效且安全,尤其在改善僵硬症状方面。

研究设计与样本

  • 前瞻性多中心注册研究,纳入50-75岁膝骨关节炎患者2995例,藤黄健骨片组1471例、常规治疗组490例、联合组1034例,疗程8周,第4和8周随访。

主要发现

  • 治疗后三组VAS和WOMAC评分均显著改善(P < 0.001)。
  • 第8周藤黄健骨片组VAS评分显著改善,低于常规治疗组(P < 0.01),与联合组相当(P = 0.623)。
  • WOMAC评分显著改善(P < 0.001),组间无差异(P > 0.05);联合组WOMAC疼痛和僵硬评分优于藤黄健骨片组和常规治疗组。
  • 倾向评分匹配后,藤黄健骨片组WOMAC疼痛和僵硬评分显著低于NSAID组(P < 0.01和0.001)。
  • 常规治疗组和联合组不良事件较高(P < 0.001)。

临床怎么用

  • 膝骨关节炎患者可优先考虑藤黄健骨片治疗,尤其关注僵硬症状改善。
  • 藤黄健骨片单药在VAS改善上优于常规治疗,且不良事件较少。
  • 联合常规治疗对WOMAC疼痛和僵硬评分有额外获益,但需关注不良事件增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chinese patent medicine Tenghuang Jiangu tablet (THJGT) is frequently used to treat knee osteoarthritis (KOA). AIM: This prospective multicenter registry study investigated the effectiveness and safety of THJGT in treating KOA. MATERIALS AND METHODS: Patients with KOA aged 50-75 years were preferentially treated with THJGT, other nonsurgical conventional treatments (CTs), or both. The treatment duration was 8 weeks, with follow-ups at weeks 4 and 8. The visual analog scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were the efficacy assessments. Adverse events and drug reactions were evaluated to assess the safety of THJGT. Propensity score matching (PSM) was used for the subgroup analysis. RESULTS: From September 2019 to January 2021, a total of 2995 participants were included, with 1471 in THJGT group, 490 in CT group and 1034 in THJGT + CT group. After treatment, the VAS and WOMAC scores in the three groups improved significantly (P < 0.001). At week 8, the VAS scores in the THJGT group significantly improved, were lower than those in the CT group (P < 0.01), and were comparable to those in the THJGT + CT group (P = 0.623). The WOMAC scores significantly improved (P < 0.001), with no differences between groups (P > 0.05). The WOMAC pain and stiffness scores were better in the THJGT + CT than in the THJGT and CT groups. PSM revealed that the WOMAC pain and stiffness scores were significantly lower in the THJGT than in the nonsteroidal anti-inflammatory drugs (NSAID) group (P < 0.01 and 0.001). Adverse events were higher in the CT and THJGT + CT groups (P < 0.001). CONCLUSION: THJGT is effective and safe for treating KOA, particularly in improving stiffness symptoms.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Zheng Z, Wang X, Mi B, et al. Tenghuang Jiangu tablet in knee osteoarthritis therapy: A prospective multicenter registry study in China. J Ethnopharmacol. 2025. PMID: 40023343. doi:10.1016/j.jep.2025.119525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。